Powered by: Motilal Oswal
2026-11-16 12:52:30 pm | Source: Geojit Financial Services
Buy Aurobindo Pharma Ltd For Target Rs.2,111 By Geojit Financial Services Ltd
Buy Aurobindo Pharma Ltd For Target Rs.2,111 By Geojit Financial Services Ltd

Broad-based Growth Drives Performance

Aurobindo Pharma Ltd (ARBP) is a leading vertically integrated pharmaceutical company. Its business units comprise formulations, custom synthesis, peptides, aurozymes, research and development and active pharmaceutical ingredients (API).

* Revenue grew 23.9% YoY to a record Rs. 10,263cr in Q2FY27, supported by broadbased growth across formulations and APIs, successful integration of Lannett Company LLC, strong injectables momentum and contribution from differentiated product launches.

* US formulations revenue grew 25.2% YoY to Rs. 4,555cr, aided by Lannett consolidation, volume expansion and the ramp-up of injectables.

* Europe revenue rose 27.5% YoY to Rs. 3,161cr in the quarter on robust execution, an expanding product portfolio and improved supply chain support.

* EBITDA increased 28.5% YoY to Rs. 2,156cr, while the margin expanded 70bps to 21.0%, driven by scale benefits, a stronger product mix, manufacturing efficiencies and improving operating leverage.

Outlook & Valuation

Aurobindo Pharma delivered another strong quarter, supported by broad-based momentum across its core formulations businesses, continued growth in key geographies and steady progress in differentiated segments. The successful integration of Lannett further enhances its US franchise and expands opportunities in complex and controlled substances. Additionally, advancements in biosimilars, biologics contract manufacturing and Contract Development and Manufacturing Organisation (CDMO) initiatives provide multiple medium-term growth avenues beyond the traditional generics portfolio. Management remains focused on sustaining profitability through an improved product mix, operating leverage and better utilisation of recently established capacities. Key monitorable remains further regulatory action at the Lannett facility. Therefore, we retain our BUY rating on the stock with a revised target price of Rs. 2,111, based on 22x FY28E Adj. EPS.

Key Concall Highlights

* Management reiterated FY27 guidance of double-digit revenue growth, an EBITDA margin above 21%, and EBITDA exceeding Rs. 8,000cr.

* The acquisition of Lannett Company LLC was completed for $245.7mn, expanding the US product portfolio and manufacturing capabilities.

* The company acquired A1 Biochem Labs, strengthening integrated contract research, development and manufacturing organisation capabilities with over 800 development projects experience.

* Launched gAdvair and received approval for gQVAR, marking important progress in its high-value respiratory portfolio.

* The oral solid dosage facility in China has started gaining traction with ~15 products commercialised and management expects it to achieve break-even during the current quarter.

* The Raleigh facility received Voluntary Action Indicated status and is expected to become a meaningful platform for inhalation, transdermal and dermatology products over the coming quarters.

* Europe continues to deliver above industry growth with management confident of sustaining double-digit expansion.

 

For More Geojit Financial Services Ltd Disclaimer https://www.geojit.com/disclaimer
SEBI Registration Number: INH200000345

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here